$ARMP
Armata Pharmaceuticals, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024003706 Filed on March 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $966.0K $1.528M $4.529M
YoY Change 21.36% 45.39% -17.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.178M $3.179M $11.65M
YoY Change 25.22% 75.64% 56.64%
% of Gross Profit
Research & Development $8.016M $7.928M $33.77M
YoY Change -16.53% -17.15% -3.56%
% of Gross Profit
Depreciation & Amortization $317.0K $292.0K $972.0K
YoY Change 58.5% 19.18% 8.0%
% of Gross Profit
Operating Expenses $11.19M $11.11M $45.42M
YoY Change -7.81% -2.39% 6.98%
Operating Profit -$10.23M -$40.89M
YoY Change -9.85% 10.68%
Interest Expense $1.820M -$10.27M -$24.29M
YoY Change -157.89% -73442.86%
% of Operating Profit
Other Income/Expense, Net -$14.79M -$28.16M
YoY Change 370.52% -97186.21%
Pretax Income -$25.02M -$19.85M -$69.05K
YoY Change 72.68% 92.43% -99.81%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$25.02M -$19.85M -$69.05M
YoY Change 72.68% 92.43% 87.03%
Net Earnings / Revenue -2590.17% -1298.89% -1524.51%
Basic Earnings Per Share -$0.69 -$1.91
Diluted Earnings Per Share -$0.69 -$0.55 -$1.91
COMMON SHARES
Basic Shares Outstanding 36.15M 36.15M 36.08M
Diluted Shares Outstanding 36.12M 36.08M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.86M $13.52M $13.52M
YoY Change 50.8% -8.95% -8.95%
Cash & Equivalents $37.90M $13.50M $13.52M
Short-Term Investments
Other Short-Term Assets $1.714M $3.363M $2.265M
YoY Change -87.29% -72.42% -81.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables $1.714M $3.363M
Total Short-Term Assets $41.72M $19.15M $19.15M
YoY Change 8.09% -29.19% -29.19%
LONG-TERM ASSETS
Property, Plant & Equipment $12.70M $12.56M $57.28M
YoY Change 133.58% 247.22% 22.77%
Goodwill $3.490M $3.490M
YoY Change 0.0% 0.0%
Intangibles $10.26M $10.26M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $2.470M $2.470M $8.190M
YoY Change 0.69% 1.69% -2.37%
Total Long-Term Assets $78.64M $79.21M $79.21M
YoY Change 12.05% 15.16% 15.16%
TOTAL ASSETS
Total Short-Term Assets $41.72M $19.15M $19.15M
Total Long-Term Assets $78.64M $79.21M $79.21M
Total Assets $120.4M $98.36M $98.36M
YoY Change 10.64% 2.64% 2.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.057M $1.585M $4.606M
YoY Change -58.86% -5.54% 6.42%
Accrued Expenses $9.181M $11.33M $11.33M
YoY Change -34.55% -44.84% -44.84%
Deferred Revenue
YoY Change
Short-Term Debt $71.66M $0.00 $0.00
YoY Change 121.25%
Long-Term Debt Due $25.01M
YoY Change
Total Short-Term Liabilities $110.0M $16.46M $16.46M
YoY Change 114.03% -33.82% -33.82%
LONG-TERM LIABILITIES
Long-Term Debt $35.37M $82.31M $82.31M
YoY Change
Other Long-Term Liabilities $28.38M $28.58M $28.58M
YoY Change -10.88% -10.13% -10.13%
Total Long-Term Liabilities $63.74M $110.9M $110.9M
YoY Change 100.2% 248.67% 248.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $110.0M $16.46M $16.46M
Total Long-Term Liabilities $63.74M $110.9M $110.9M
Total Liabilities $176.9M $130.4M $130.4M
YoY Change 104.87% 118.27% 118.27%
SHAREHOLDERS EQUITY
Retained Earnings -$333.8M -$308.8M
YoY Change 31.28% 28.79%
Common Stock $361.0K $361.0K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$56.51M -$32.07M -$32.06M
YoY Change
Total Liabilities & Shareholders Equity $120.4M $98.36M $98.36M
YoY Change 10.64% 2.64% 2.64%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$25.02M -$19.85M -$69.05M
YoY Change 72.68% 92.43% 87.03%
Depreciation, Depletion And Amortization $317.0K $292.0K $972.0K
YoY Change 58.5% 19.18% 8.0%
Cash From Operating Activities -$10.58M -$8.103M -$47.42M
YoY Change -39.76% -22.72% 46.0%
INVESTING ACTIVITIES
Capital Expenditures $250.0K $2.404M $8.144M
YoY Change -87.56% -628.35% 268.34%
Acquisitions
YoY Change
Other Investing Activities $10.00K $10.00K
YoY Change
Cash From Investing Activities -$250.0K -$2.394M -$8.134M
YoY Change -87.56% -626.15% 267.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.93M -42.00K 53.99M
YoY Change 18.03% -91.6% 22.66%
NET CHANGE
Cash From Operating Activities -10.58M -8.103M -47.42M
Cash From Investing Activities -250.0K -2.394M -8.134M
Cash From Financing Activities 34.93M -42.00K 53.99M
Net Change In Cash 24.10M -10.54M -1.569M
YoY Change 140.63% 0.09% -116.83%
FREE CASH FLOW
Cash From Operating Activities -$10.58M -$8.103M -$47.42M
Capital Expenditures $250.0K $2.404M $8.144M
Free Cash Flow -$10.83M -$10.51M -$55.57M
YoY Change -44.67% 4.76% 60.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration
PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36144706
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36122932
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000921114
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37544
CY2023 dei Entity Registrant Name
EntityRegistrantName
ARMATA PHARMACEUTICALS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1549568
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
5005 McConnell Avenue
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90066
CY2023 dei City Area Code
CityAreaCode
310
CY2023 dei Local Phone Number
LocalPhoneNumber
665-2928
CY2023 dei Security12b Title
Security12bTitle
Common Stock
CY2023 dei Trading Symbol
TradingSymbol
ARMP
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
12500000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36148539
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Diego, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13523000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14852000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2265000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3664000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3363000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8531000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19151000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27047000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5720000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5960000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12559000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3617000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44717000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43035000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2023Q4 us-gaap Goodwill
Goodwill
3490000
CY2022Q4 us-gaap Goodwill
Goodwill
3490000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2470000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2429000
CY2023Q4 us-gaap Assets
Assets
98363000
CY2022Q4 us-gaap Assets
Assets
95834000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5689000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6034000
CY2023Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
768000
CY2022Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1828000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9481000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17011000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
523000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16461000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24873000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28583000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31804000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
58633000
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
23674000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2023Q4 us-gaap Liabilities
Liabilities
130428000
CY2022Q4 us-gaap Liabilities
Liabilities
59754000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36122932
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36122932
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36144706
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36144706
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
361000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
361000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
276393000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
275493000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308819000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239774000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32065000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36080000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98363000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95834000
CY2023 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
4529000
CY2022 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
5508000
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
33770000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35017000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11649000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7437000
CY2023 us-gaap Operating Expenses
OperatingExpenses
45419000
CY2022 us-gaap Operating Expenses
OperatingExpenses
42454000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-40890000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-36946000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
179000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
2626000
CY2023 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-21845000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3863000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-28155000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-69045000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36917000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36075555
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36075555
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34294124
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34294124
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25397000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44391000
CY2022 armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
21000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
125000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3105000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36917000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36080000
CY2023 armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
43000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
938000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-69045000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32065000
CY2023 us-gaap Profit Loss
ProfitLoss
-69045000
CY2022 us-gaap Profit Loss
ProfitLoss
-36917000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
972000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
892000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
938000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3105000
CY2023 armp Increase Decrease Fair Value Of Liabilities
IncreaseDecreaseFairValueOfLiabilities
21845000
CY2023 us-gaap Other Noncash Expense
OtherNoncashExpense
2573000
CY2023 armp Noncash Interest Income
NoncashInterestIncome
22000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3863000
CY2023 armp Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1018000
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-81000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4826000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7662000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
39000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3665000
CY2023 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-1060000
CY2022 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
793000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-13451000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
3643000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47423000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32481000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8144000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2211000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8134000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2211000
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
29101000
CY2023 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
24925000
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
500000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
44391000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
43000
CY2023 armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
5000
CY2022 armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
125000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53988000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44016000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1569000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9324000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20812000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11488000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19243000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20812000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2700000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8669000
CY2023 us-gaap Contribution Of Property
ContributionOfProperty
217000
CY2022 us-gaap Contribution Of Property
ContributionOfProperty
78000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13523000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14852000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5720000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5960000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19243000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20812000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308800000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13500000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the convertible debt, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;">Concentration of Credit Risks and Certain Other Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. As of December 31, 2023 and 2022, cash, cash equivalents and marketable securities were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions. Investments are restricted, in accordance with the Company’s investment policy, to a concentration limit per issuer or sector.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Other receivables represents amounts due from Medical Technology Enterprise Consortium (Note 13) and reimbursement for tenant improvements (Note 12).</span></p>
CY2023 armp Number Of Standby Letters Of Credit Included In Restricted Cash
NumberOfStandbyLettersOfCreditIncludedInRestrictedCash
2
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2023 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
0
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
500000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44024924
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24031807
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24380000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14720000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11821000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11103000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12559000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3617000
CY2023 us-gaap Depreciation
Depreciation
1000000.0
CY2023 us-gaap Depreciation
Depreciation
1000000.0
CY2022 us-gaap Depreciation
Depreciation
900000
CY2023Q4 armp Property And Equipment Not In Use Included In Laboratory Equipment
PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment
8100000
CY2022Q4 armp Property And Equipment Not In Use Included In Laboratory Equipment
PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment
1000000.0
CY2023Q4 armp Tenant Improvement Receivable Current
TenantImprovementReceivableCurrent
1835000
CY2022Q4 armp Tenant Improvement Receivable Current
TenantImprovementReceivableCurrent
6595000
CY2023Q4 armp Grant And Award Receivable Current
GrantAndAwardReceivableCurrent
1528000
CY2022Q4 armp Grant And Award Receivable Current
GrantAndAwardReceivableCurrent
1936000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3363000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
8531000
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24512459
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1585000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1678000
CY2023Q4 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
3021000
CY2022Q4 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
2650000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1083000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1706000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5689000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6034000
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
2600000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19365847
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20549338
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3165216
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3352803
CY2023Q4 us-gaap Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares
EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
9748
CY2022Q4 us-gaap Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares
EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
9748
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19365847
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20549338
CY2023Q4 armp Shares Issuable Upon Conversion Of Convertible Debt
SharesIssuableUponConversionOfConvertibleDebt
21293861
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
46402832
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3352803
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.32
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
330266
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.39
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1500
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.15
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
516353
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.94
CY2023 armp Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue
1000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3165216
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
429
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3165216
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
429
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2176275
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.01
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
115000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.97
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5100000
CY2023Q3 armp Share Based Payment Arrangement Expense Reversed
ShareBasedPaymentArrangementExpenseReversed
600000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
938000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3105000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-68182
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-32228
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-863
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4689
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69045
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36917
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
46591
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42525
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
21431
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
19103
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2083
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3192
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
856
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
929
CY2023Q4 armp Deferred Tax Asset Lease Obligation
DeferredTaxAssetLeaseObligation
13899
CY2022Q4 armp Deferred Tax Asset Lease Obligation
DeferredTaxAssetLeaseObligation
13660
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1907
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1452
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
86767
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
80861
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
75166
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
68818
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
11601
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
12043
CY2023Q4 armp Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
11510
CY2022Q4 armp Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
12043
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3077
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3077
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
91
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
14678
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
15120
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3077
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3077
CY2023Q4 armp Operating Loss Carryforwards Not Subject To Expiration
OperatingLossCarryforwardsNotSubjectToExpiration
113100000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6300000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.029
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.073
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.016
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.002
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.093
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.286
CY2023 armp Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Extinguishment Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent
-0.012
CY2022 armp Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Extinguishment Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent
0.000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.033
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2023 armp Effective Income Tax Rate Reconciliation Nondeductible Expense Fair Value Adjustment On Convertible Debt Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent
-0.066
CY2022 armp Effective Income Tax Rate Reconciliation Nondeductible Expense Fair Value Adjustment On Convertible Debt Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent
0.000
CY2023 armp Income Tax Rate Reconciliation Permanent Differences1
IncomeTaxRateReconciliationPermanentDifferences1
-0.019
CY2022 armp Income Tax Rate Reconciliation Permanent Differences1
IncomeTaxRateReconciliationPermanentDifferences1
0.005
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q2 armp Operating Lease Base Rent
OperatingLeaseBaseRent
1900000
CY2020Q2 armp Annual Increase In Rent Percentage
AnnualIncreaseInRentPercentage
0.03
CY2020Q2 armp Operating Lease Base Rent End Of Lease Term
OperatingLeaseBaseRentEndOfLeaseTerm
2500000
CY2020Q2 armp Lease And Rental Abatement Credit Period
LeaseAndRentalAbatementCreditPeriod
P6M
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11700000
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1289
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11000000.0
CY2021Q4 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P16Y
CY2021Q4 armp Base Annual Rent To Be Paid Year Three
BaseAnnualRentToBePaidYearThree
250000
CY2021Q4 armp Maximum Allowance For Tenant Improvements Receivable
MaximumAllowanceForTenantImprovementsReceivable
7300000
CY2021Q4 armp Proceeds From Tenant Allowances
ProceedsFromTenantAllowances
5400000
CY2022Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.118
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
37000000.0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33800000
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
5000000.0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9899000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5307000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5724000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5452000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5616000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
43181000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
75179000
CY2023Q4 armp Short Term Variable Lease Payment Amount
ShortTermVariableLeasePaymentAmount
5386000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
31729000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
38064000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9481000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28583000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
7400000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
6300000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
3500000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2700000
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-003706-index-headers.html Edgar Link pending
0001558370-24-003706-index.html Edgar Link pending
0001558370-24-003706.txt Edgar Link pending
0001558370-24-003706-xbrl.zip Edgar Link pending
armp-20231231.xsd Edgar Link pending
armp-20231231x10k.htm Edgar Link pending
armp-20231231x10k003.jpg Edgar Link pending
armp-20231231x10k004.jpg Edgar Link pending
armp-20231231x10k005.jpg Edgar Link pending
armp-20231231x10k006.jpg Edgar Link pending
armp-20231231x10k007.jpg Edgar Link pending
armp-20231231x10k008.jpg Edgar Link pending
armp-20231231x10k009.jpg Edgar Link pending
armp-20231231x10k010.jpg Edgar Link pending
armp-20231231x10k011.jpg Edgar Link pending
armp-20231231xex10d28.htm Edgar Link pending
armp-20231231xex10d28001.jpg Edgar Link pending
armp-20231231xex21d1.htm Edgar Link pending
armp-20231231xex23d1.htm Edgar Link pending
armp-20231231xex31d1.htm Edgar Link pending
armp-20231231xex31d2.htm Edgar Link pending
armp-20231231xex32d1.htm Edgar Link pending
armp-20231231xex32d2.htm Edgar Link pending
armp-20231231xex4d9.htm Edgar Link pending
armp-20231231xex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
armp-20231231_def.xml Edgar Link unprocessable
armp-20231231_lab.xml Edgar Link unprocessable
armp-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
armp-20231231x10k_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
armp-20231231_cal.xml Edgar Link unprocessable